Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Editorials |1 July 2014

Screening for Hepatitis B Virus Infection: A Public Health Imperative Free

Ruma Rajbhandari, MD, MPH; Raymond T. Chung, MD

Ruma Rajbhandari, MD, MPH
From Massachusetts General Hospital; Boston, Massachusetts.

Raymond T. Chung, MD
From Massachusetts General Hospital; Boston, Massachusetts.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From Massachusetts General Hospital; Boston, Massachusetts.

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1153.

    Requests for Single Reprints: Raymond T. Chung, MD, Liver Center and Gastrointestinal Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114.

    This article was published online first at www.annals.org on 27 May 2014.

    Current Author Addresses: Drs. Rajbhandari and Chung: Liver Center and Gastrointestinal Division, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link
Chronic hepatitis B virus (HBV) infection is a major public health problem, affecting an estimated 400 million persons worldwide. The GBD (Global Burden of Disease) study attributed 786 000 deaths to HBV infection in 2010 as a result of cirrhosis, liver failure, and hepatocellular carcinoma (HCC), making HBV the 15th leading cause of death worldwide. In the United States, 1.25 million persons are infected with HBV and those who develop chronic infection die an average of 22 years earlier than those without infection (1). The burden of HBV infection is expected to increase in the face of immigration patterns into the United States from highly endemic countries.
This issue includes the most recent U.S. Preventive Services Task Force (USPSTF) recommendations on screening for HBV infection in nonpregnant adults and adolescents (2). The new recommendations advocate screening for HBV infection in persons at high risk for infection, such as those born in countries with a prevalence of HBV infection of 2% or greater, HIV-positive persons, injection drug users, household contacts of persons with HBV infection, men who have sex with men, and persons who are immunosuppressed or receiving hemodialysis. The recommendations are given a grade of B, which indicates that there is high certainty that the net benefit is moderate or that there is moderate certainty that the net benefit is moderate to substantial. These recommendations are a dramatic and welcome upgrade from the 2004 USPSTF guidelines, which issued a grade D recommendation against screening asymptomatic persons for HBV infection.
These updated recommendations are long overdue. Since 2001, when its first practice guideline on chronic HBV infection was published, the American Association for the Study of Liver Diseases has recommended screening for HBV infection in high-risk groups (3). The Centers for Disease Control and Prevention has recommended hepatitis B surface antigen screening for high-risk groups, such as pregnant women and infants born to HBV-infected mothers, household contacts and sexual partners of infected persons, and other persons with exposures to infectious blood or body fluids, since at least 2005 (4).
Further, there has been continued progress in treatment of HBV infection. The U.S. Food and Drug Administration has approved 7 antiviral drugs for treating chronic HBV infection: interferon-α2b, pegylated interferon-α2a, lamivudine, adefovir, entecavir, telbivudine, and tenofovir. Entecavir, tenofovir, and pegylated interferon-α2a are the current first-line agents.
The case for suppression of HBV replication is compelling. First, in the REVEAL-HBV (Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus) study, serum HBV DNA levels, a marker of replication, were shown to be significantly and independently associated with the incidence of HCC, cirrhosis, and liver-related deaths (5). Second, the preponderance of evidence supports the clinical benefits of virologic suppression, including decreased incidence of hepatic decompensation and HCC, the reversal of cirrhosis, and the clinical stabilization of hepatic failure (6–9).
The USPSTF acknowledged these arguments in its 2014 deliberations. However, considering that the U.S. Food and Drug Administration had already approved several of these anti-HBV agents by 2002 and that much of the data showing clinical benefit of HBV suppression were available by 2004, many would argue that the USPSTF should have endorsed screening for HBV infection in high-risk populations a decade ago or at least soon thereafter. We may have thus missed an opportunity to screen many high-risk persons in the United States.
Although we are glad that the USPSTF now recommends screening, we think that the recommendations would be more useful if they provided a clearer definition of the high-risk patient. The recommendations state that “[c]linicians should exercise their judgment in deciding whether ... persons are at sufficiently high risk to warrant screening.” We worry that busy generalist clinicians do not have the time to estimate their patients’ risks for HBV infection. The USPSTF should have adopted an approach similar to that used by the Centers for Disease Control and Prevention and listed in table form all factors that render a patient high-risk.
The lack of randomized trials on the health benefits of screening for HBV infection in asymptomatic adolescents and adults contributed to the USPSTF's previous hesitancy to recommend screening (1). However, given the natural history of HBV infection, during which such clinical outcomes as cirrhosis and HCC develop 20 to 30 years after infection, a randomized, controlled trial of screening for HBV infection in asymptomatic adolescents and adults is unlikely ever to be done. In the absence of such trials, many modeling studies suggest that screening would have a large benefit and be cost-effective. For example, Veldhuijzen and colleagues (10) estimated that 1-time screening for HBV infection in the Netherlands would reduce liver disease–related mortality by 10% and be cost-effective.
Testing asymptomatic persons for chronic HBV infection meets established criteria for screening. It identifies an unrecognized health condition so that treatment can be offered before symptoms of chronic HBV infection, cirrhosis, or HCC develop. Testing for HBV infection also allows interventions to be implemented that reduce the likelihood of continued transmission of the infection to others. In addition, tests for HBV infection are widely available, cheap, and accurate.
We laud the USPSTF for its 2014 recommendations that will enable widespread adoption of screening for HBV infection in high-risk populations. Under the Patient Protection and Affordable Care Act, most private insurers and all Medicaid programs must cover any preventive service given a grade A or B recommendation by the USPSTF. In light of this powerful mandate, we believe that the USPSTF should make every effort to ensure that its recommendations do not lag behind the evidence, because the administration of potentially high-impact antiviral therapy hinges on timely identification of infected persons.

References

  1. Ly
    KN
    ,  
    Xing
    J
    ,  
    Klevens
    RM
    ,  
    Jiles
    RB
    ,  
    Ward
    JW
    ,  
    Holmberg
    SD
    .  
    The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.
    Ann Intern Med
    2012
    156
    271
    8
    CrossRef
    PubMed
  2. LeFevre
    ML
    .  
    U.S. Preventive Services Task Force
    Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement.
    Ann Intern Med
    2014
    161
    58
    66
  3. Lok
    AS
    ,  
    McMahon
    BJ
    .  
    Practice Guidelines Committee, American Association for the Study of Liver Diseases
    Chronic hepatitis B.
    Hepatology
    2001
    34
    1225
    41
    PubMed
    CrossRef
    PubMed
  4. Mast
    EE
    ,  
    Margolis
    HS
    ,  
    Fiore
    AE
    ,  
    Brink
    EW
    ,  
    Goldstein
    ST
    ,  
    Wang
    SA
    .  
    et al
    Advisory Committee on Immunization Practices (ACIP)
    A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents.
    MMWR Recomm Rep
    2005
    54
    RR-16
    1
    31
    PubMed
    PubMed
  5. Chen
    CJ
    ,  
    Iloeje
    UH
    ,  
    Yang
    HI
    .  
    Long-term outcomes in hepatitis B: the REVEAL-HBV study.
    Clin Liver Dis
    2007
    11
    797
    816
    PubMed
    CrossRef
    PubMed
  6. Liaw
    YF
    ,  
    Sung
    JJ
    ,  
    Chow
    WC
    ,  
    Farrell
    G
    ,  
    Lee
    CZ
    ,  
    Yuen
    H
    .  
    et al
    Cirrhosis Asian Lamivudine Multicentre Study Group
    Lamivudine for patients with chronic hepatitis B and advanced liver disease.
    N Engl J Med
    2004
    351
    1521
    31
    PubMed
    CrossRef
    PubMed
  7. Villeneuve
    JP
    ,  
    Condreay
    LD
    ,  
    Willems
    B
    ,  
    Pomier-Layrargues
    G
    ,  
    Fenyves
    D
    ,  
    Bilodeau
    M
    .  
    et al
    Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Hepatology
    2000
    31
    207
    10
    PubMed
    CrossRef
    PubMed
  8. Chang
    TT
    ,  
    Liaw
    YF
    ,  
    Wu
    SS
    ,  
    Schiff
    E
    ,  
    Han
    KH
    ,  
    Lai
    CL
    .  
    et al
    Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
    Hepatology
    2010
    52
    886
    93
    PubMed
    CrossRef
    PubMed
  9. Papatheodoridis
    GV
    ,  
    Lampertico
    P
    ,  
    Manolakopoulos
    S
    ,  
    Lok
    A
    .  
    Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
    J Hepatol
    2010
    53
    348
    56
    PubMed
    CrossRef
    PubMed
  10. Veldhuijzen
    IK
    ,  
    Toy
    M
    ,  
    Hahné
    SJ
    ,  
    De Wit
    GA
    ,  
    Schalm
    SW
    ,  
    de Man
    RA
    .  
    et al
    Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Gastroenterology
    2010
    138
    522
    30
    PubMed
    CrossRef
    PubMed

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Rajbhandari R, Chung RT. Screening for Hepatitis B Virus Infection: A Public Health Imperative. Ann Intern Med. ;161:76–77. doi: 10.7326/M14-1153

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2014;161(1):76-77.

DOI: 10.7326/M14-1153

1 Citations

See Also

Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement
Screening for Hepatitis B Virus Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation
View MoreView Less

Related Articles

Expanding the Public Health Approach to Gun Violence Prevention
Annals of Internal Medicine; 169 (10): 723-724
Elements of a Comprehensive Public Health Response to the Opioid Crisis
Annals of Internal Medicine; 169 (10): 712-715
Dying Healthy: Public Health Priorities for Fixed Population Life Expectancies
Annals of Internal Medicine; 169 (8): 568-569
Public Health Research on Gun Violence: Long Overdue
Annals of Internal Medicine; 168 (12): 876-877
View MoreView Less

Related Topics

Gastroenterology/Hepatology
Infectious Disease
Viral Hepatitis

Gastroenterology/Hepatology, Infectious Disease, Viral Hepatitis.

PubMed Articles

Tracking Multimorbidity Changes in Racial/Ethnic Diverse Populations over Time: Issues and Considerations.
J Gerontol A Biol Sci Med Sci 2019.
[Ocular lesions in HIV-infected patients of the ophthalmic hospitals].
Vestn Oftalmol 2018;134(6):25-32.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×